Peptide Manufacturing Enters the Industrial Era avatar David Alvaro, Ph.D. Editor in Chief Pharma's Almanac

https://www.pharmasalmanac.com/articles/peptide-manufacturing-enters-the-industrial-era Key Takeaways GLP-1 demand has transformed peptide manufacturing from a specialized capability into a strategic capacity challenge requiring larger-scale synthesis, purification, lyophilization, and supply-chain planning. Peptide API manufacturing depends on more than solid-phase peptide synthesis capacity; bottlenecks can emerge in raw materials, purification, freeze-drying, analytical release, fill-finish, and distribution. High solvent and reagent use makes peptide manufacturing both an environmental and economic challenge, linking sustainability directly to cost, throughput, waste handling, and facility utilization. CDMOs are becoming strategic partners in peptide development as sponsors seek expertise in process development, scale-up, impurity control, quality systems, and long-term supply security. Recent investments by peptide manufacturers and pharmaceutical companies show that industrial-scale peptide capacity is becoming a critical enabler of future therapeutic growth.